William R. Gesztes received his M.D in medicine from Semmelweis University in 2015, and is a genitourinary pathology subspecialty trainee
(2024-2025) at Memorial Sloan Kettering Cancer Center in New York. He previously trained at the George Washington University Hospital and the VA Medical Hospital in Washington D.C. as a resident (combined AP/CP) and cytopathology fellow. Before pursuing a pathology residency, Dr. Gesztes completed a post-doctorate research fellowship at the Center for Prostate Disease Research (CPDR) in Bethesda, Maryland. His research topics include prostate cancer, risk stratification, biomarkers, TP53, p53, artificial intelligence (AI)/digital pathology and thyroid cancer related research. His prior research published in Nature: Scientific Reports showed a striking hazard ratio (HR: 7.98) for predicting metastatic prostate cancer in patients who had evidence of both p53 overexpression (>5%) and lymphovascular invasion (LVI). The question remains how best to characterize p53 overexpression in prostate tumors. This study investigates the two most common approaches for evaluating p53 nuclear expression, independent of tissue source, in a unique minority population, as part of an effort to better inform this consensus-building process.
